Restart Life Sciences Corp. reports developments in its better-for-you functional food and consumer packaged goods portfolio. The company operates through Holy Crap Foods Inc., a wholly owned subsidiary focused on superseed cereals, oatmeal and related gut-health products, and also references wellness product lines such as BrainQ™ and BrainBalls™ for cognitive health.
Recurring updates cover Holy Crap Foods integration, wholesale and e-commerce sales channels, Amazon Canada and Walmart.ca distribution, certified manufacturing capabilities, product development with the University of Manitoba’s Richardson Centre for Food Technology and Research, and internal infrastructure for brand scaling. Company news also includes board appointments, capital-markets oversight, related-party share issuance disclosures and broader operational execution across its functional wellness platform.
Nova Mentis Life Science Corp. has received approval from the U.S. FDA for its psilocybin drug's Orphan Drug Application targeting Fragile X Syndrome (FXS), the leading inherited cause of autism. This designation grants NOVA significant benefits, including seven to ten years of market exclusivity and eligibility for federal tax credits. Notably, NOVA is the first biotech firm to have psilocybin recognized for FXS treatment by both FDA and EMA. The company plans to initiate phase 2 clinical studies supported by real-world evidence data.
Nova Mentis Life Science Corp. (NMLSF) announced it received orphan drug designation from the European Medicines Agency for its psilocybin drug targeting fragile X syndrome (FXS), a leading genetic cause of autism spectrum disorder. This designation accelerates the drug approval process, providing benefits like ten years of market exclusivity and grants. CEO Will Rascan emphasized the milestone's significance for advancing clinical programs in Europe, aiming for a phase 2 study. Currently, there are no effective treatments for FXS, making this development a critical step toward addressing an unmet medical need.
Nova Mentis Life Science Corp. has partnered with Mycrodose Therapeutics to develop patented products targeting neuroinflammatory disorders, including fragile X syndrome and autism spectrum disorder. This collaboration aims to leverage Mycrodose's advanced drug delivery systems and NOVA's psilocybin therapeutic, which has shown promising preclinical results. The partnership could broaden the patient base for psilocybin treatments, especially in pediatric applications. NOVA has applied for Orphan Drug designation, providing significant financial and regulatory benefits.